Reslizumab
Low persistence in biologic therapy linked to asthma exacerbations, steroid use
SAN FRANCISCO — Patients with asthma who did not persist with biologic treatment had more exacerbations and used more oral corticosteroids, according to an abstract presented at the American Thoracic Society International Conference.
Dupilumab, tezepelumab lead biologic initiations for severe asthma
SAN DIEGO — Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here.
Adherence to asthma biologics varies by therapy given, tends to be low
SAN DIEGO — Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.
Dupilumab leads biologics in reducing asthma exacerbations
Biologics designed to counter type 2 inflammation reduced asthma exacerbations in real world settings, with dupilumab having the most impact, according to a study in he Journal of Allergy and Clinical Immunology: In Practice.
Biologics comparably effective in controlling eosinophilic severe asthma symptoms
Mepolizumab, reslizumab and dupilumab were equally effective in controlling symptoms among patients with eosinophilic severe asthma, according to a study published in Annals of Allergy, Asthma & Immunology.
Experts debate use of dual biologics to treat severe asthma
WASHINGTON — A debate at the American Thoracic Society International Conference changed some minds about whether providers could or should combine and overlap biologic treatments to treat severe asthma.